KRRO VS MRNS Stock Comparison
Performance
KRRO100/100
100/100
KRRO returned 192.66% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
MRNS100/100
100/100
MRNS returned 37.45% in the last 12 months. Based on SPY's performance of -13.33%, its performance is above average giving it a score of 100 of 100.
Earnings
KRRO100/100
100/100
KRRO has missed earnings 0 times in the last 20 quarters.
MRNS10/100
10/100
MRNS has missed earnings 8 times in the last 20 quarters.
Volatility
KRRO100/100
100/100
KRRO has had a higher than average amount of volatility over the last 12 months giving it a score of 100 of 100.
MRNS51/100
51/100
MRNS has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.
Analyst Price Targets
KRRO
"Analyst Price Targets" not found for KRRO
MRNS75/100
75/100
1 analysts offer 12-month price targets for MRNS. Together, they have an average target of 0, the most optimistic target put MRNS at 0 within 12-months and the most pessimistic has MRNS at 0.
Technicals
KRRO
"Technicals" not found for KRRO
MRNS36/100
36/100
MRNS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
Profit
KRRO
"Profit" not found for KRRO
MRNS10/100
10/100
Out of the last 20 quarters, MRNS has had 1 profitable quarters and has increased their profits year over year on 1 of them.
All score calculations are broken down here to help you make more informed investing decisions
Korro Bio, Inc. Common Stock Summary
Nasdaq / KRRO
Healthcare
Biotechnology
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Marinus Pharmaceuticals, Inc Summary
Nasdaq / MRNS
Healthcare
Biotechnology
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare KRRO to other companies in the same or a similar industry.